Phase 3 CheckMate 067 trial of nivolumab and ipilimumab combination or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma | Dr James Larkin at Annual Meeting 2015 - 101271

Spotlight
Video

Phase 3 CheckMate 067 trial of nivolumab and ipilimumab combination or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma | Dr James Larkin at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden, London, UK, discusses the phase 3 CheckMate 067 trial. The results of this trial demonstrate a superior progression-free survival of nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) regimen or nivolumab monotherapy versus ipilimumab monotherapy in previously untreated advanced melanoma.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 06/10/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.